Danyal Butt
Associate Director Abbvie
Danyal Butt is a Principal Research Scientist II in Biotherapeutics and Genetic Medicine Technologies at AbbVie. He joined AbbVie in 2019 and has been leading and supporting biologics drug discovery projects in Immunology, Oncology, Neuroscience and Cell Therapy. Currently, he leads the In vivo Antibody Discovery and Sequencing Technologies Group. In addition, he co-leads the AbbVie-Harvard Alliance program area for developing antibody therapeutics against emergent pathogens. Dany’s scientific training is in immunology focused on B cell biology and antibody responses. He received his PhD at the Garvan Institute in Sydney, Australia.
Seminars
Tuesday 28th April 2026
Accelerating Antibody Discovery for Complex Targets: Digital Platforms & AI Integration for GPCRs
2:45 pm
- Digitalization and optimization of biotherapeutics discovery workflows accelerate identification of antibodies against challenging targets such as GPCRs
- Automated platforms leveraging integrated sequence, screening, and informatics data enable efficient selection from large, diverse antibody panels
- These advancements provide a foundation for AI/ML applications to address complex therapeutic targets such as GPCRs
